title: Selective inhibition of brain Na,K-ATPase by drugs.
abstract: The effect of drugs from the class of cardiac (methyldigoxin, verapamil, propranolol), antiepileptic (carbamazepine), sedative (diazepam) and antihistaminic (promethazine) drugs on Na,K-ATPase activity of plasma membranes was studied in rat brain synaptosomes. Methyldigoxin in a concentration of 0.1 mmol/l inhibits enzyme activity by 80 %. Verapamil, propranolol and promethazine in concentrations of 20, 20 and 2 mmol/l respectively, entirely inhibit the ATPase activity. Carbamazepine and diazepam in concentrations of 0.02-60 mmol/l have no effect on the activity of this enzyme. According to the drug concentrations that inhibit 50 % of enzyme activity (IC(50)), the potency can be listed in the following order: methyldigoxin promethazine verapamil ? propranolol. From the inhibition of commercially available purified Na,K-ATPase isolated from porcine cerebral cortex in the presence of chosen drugs, as well as from kinetic studies on synaptosomal plasma membranes, it may be concluded that the drugs inhibit enzyme activity, partly by acting directly on the enzyme proteins. Propranolol, verapamil and promethazine inhibitions acted in an uncompetitive manner. The results suggest that these three drugs may contribute to neurological dysfunctions and indicate the necessity to take into consideration the side effects of the investigated drugs during the treatment of various pathological conditions.
authors.affiliation: Laboratory for Molecular Biology and Endocrinology, "Vinca" Institute of Nuclear Sciences, P.O.Box 522, 11001 Belgrade. Serbia and Montenegro. ahorvat@vin.bg.ac.yu
authors.forename: A
authors.initials: A
authors.lastname: Horvat
authors.forename: T
authors.initials: T
authors.lastname: Momić
authors.forename: S
authors.initials: S
authors.lastname: Petrović
authors.forename: G
authors.initials: G
authors.lastname: Nikezić
authors.forename: M
authors.initials: M
authors.lastname: Demajo
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000201:enzymology*; D002462:Cell Membrane / Q000187:drug effects / Q000201:enzymology; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D007700:Kinetics; D008297:Male; D008520:Medigoxin / Q000494:pharmacology; D011398:Promethazine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D000254:Sodium-Potassium-Exchanging ATPase / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D013552:Swine; D013574:Synaptosomes / Q000187:drug effects / Q000201:enzymology; D014700:Verapamil / Q000494:pharmacology
chemical_list: D004791:Enzyme Inhibitors; D000255:Adenosine Triphosphate; D011433:Propranolol; D014700:Verapamil; D000254:Sodium-Potassium-Exchanging ATPase; D011398:Promethazine; D008520:Medigoxin